YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Senior Vice President of Investor Relations - Allison Wey Chairman and Chief Executive Officer - John Shannon Chief Financial Officer - Steven Pie…
Key Points Interested in Xeris Biopharma Holdings, Inc.? Here are five stocks we like better. Xeris Biopharma's second-quarter revenue rose 29% year over year to $92.1 million, driven by a 34% increase in net product revenue. Adjusted EBIT…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Stocks trading below $10 often attract retail investors looking for high-growth opportunities at relatively low entry prices. However, many of these low-priced equities can…
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list. TheFly reported on June 11 that XERS announced tha…
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. When a caller mentioned that XERS is their speculative investment, Cramer said: I know it…
Xeris Biopharma logo Key Points Interested in Xeris Biopharma Holdings, Inc.? Here are five stocks we like better. Xeris Biopharma posted strong Q1 2026 results, with total revenue up 38% year over year to $83.1 million and net product rev…
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary - Moby 2025 Performance and Strategic Execution Achieved a defining milestone of financial self-sustainability, effectively removing the need for external funding to support the…
[Fourth Quarter Q4 Profits Stock Trading Chart 3D Background] * Xeris Biopharma (XERS [https://seekingalpha.com/symbol/XERS]) is up ~4% in Monday trading after posting 2026 revenue guidance above the consensus. * The company is projecting…
Image source: The Motley Fool. DATE Monday, Mar. 2, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — John Shannon Chief Financial Officer — Steven Pieper Need a quote from a Motley Fool analyst? Email pr@fool.com Full Confe…
Xeris Biopharma logo Xeris Biopharma (NASDAQ:XERS) reported sharp top-line growth in the fourth quarter and full year 2025, highlighted by what management described as a “defining milestone” for the company: financial self-sustainability.…
Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Uniti Group (UNIT [https://seekingalpha.com/symbol/UNIT]) * The Progressive Corporation (PGR […
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurri…
The big news this week is AI may not be the economic savior that companies were hoping for. Sure, AI will help cut costs and make companies more profitable. At least, initially. What happens next is the big question. Claim 50% Off TipRanks…
Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for relacorilant, its investigational treatment for Cushing’s syndrome. The agency’s Complete Response Letter cited insuff…
Key Points It wasn't because of any news coming from the biotech. Rather, a rival's setback brought the bulls into its stock. 10 stocks we like better than Xeris Biopharma › A competitor's setback was Xeris Biopharma's (NASDAQ: XERS) gain…
Key Points It wasn't because of any news coming from the biotech. Rather, a rival's setback brought the bulls into its stock.10 stocks we like better than Xeris Biopharma › A competitor's setback was Xeris Biopharma's (NASDAQ: XERS) gain o…
We came across a bullish thesis on Xeris Biopharma Holdings, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research and Rudy Does Research. In this article, we will summarize the bulls’ thesis on XERS. Xeris Biopharma…
In this article, we will take a look at the top 7 hidden multibagger stocks to invest in. Multibaggers often take the limelight because of their stellar returns, but it isn’t always easy to catch these multibaggers while they are in the pr…
Shareholders of Principal Financial Group Inc (Symbol: PFG) looking to boost their income beyond the stock's 3.9% annualized dividend yield can sell the January 2026 covered call at the $85 strike and collect the premium based on the $1.75…
Xeris Biopharma (XERS) shares ended the last trading session 14.2% higher at $9.27. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.7% gain ove…
In recent trading, shares of Xeris Biopharma Holdings Inc (Symbol: XERS) have crossed above the average analyst 12-month target price of $9.00, changing hands for $9.27/share. When a stock reaches the target an analyst has set, the analyst…
After a period of weakness, biotech stocks are on the upswing, experts say. But bear in mind: Putting your money into biotechnology companies can lead you on something of a wild ride. The field, which uses living organisms, cells and biolo…
Last week, the three most widely followed U.S. indexes The Nasdaq Composite, the S&P 500, and the Dow Jones Industrial Average slipped 3.21%, 2.79%, and 2.60%, respectively. A sharp sell-off began due to heightened uncertainty after the go…
Have you been paying attention to shares of Xeris Biopharma (XERS)? Shares have been on the move with the stock up 5.3% over the past month. The stock hit a new 52-week high of $8.37 in the previous session. Xeris Biopharma has gained 145.…
We recently published 10 Best Biotech Stocks to Buy Under $10. Xeris Biopharma Holdings, Inc. is placed among them. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a Chicago-based commercial-stage biopharmaceutical company focused on thera…
Investing.com - H.C. Wainwright has assumed coverage on Xeris Pharmaceuticals (NASDAQ:XERS), currently trading at $7.20 with a market capitalization of $1.16 billion, with a Buy rating and a $10.00 price target, according to a research not…
Earnings Call Insights: Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 MANAGEMENT VIEW * John P. Shannon, CEO, reported "the strong momentum we established in the first quarter continued into the second quarter, driving another period of in…
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT AVAH [https://www.chartmill.com/stock/quote/AVAH/profile] 4…
Xeris Biopharma Holdings Inc (NASDAQ:XERS [https://www.chartmill.com/stock/quote/XERS]) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction in pre-market trading. The comp…
Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * ConocoPhillips (COP [https://seekingalpha.com/symbol…
[Stock market Exchanges Volume Leaders Digital Tableau interface background] bestsale Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impa…
Insights from the First Quarter of 2025 Prem Watsa (Trades, Portfolio), a renowned value investor and the driving force behind Fairfax Financial, recently submitted his 13F filing for the first quarter of 2025. Born in Mangalore, India, Wa…
We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look at where Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) stands against other unstoppable growth stocks to invest in n…
We recently published a list of 10 Best Multibagger Penny Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Xeris Biopharma Holdings Inc. (NASDAQ:XERS) stands against other best multibagger penn…
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the ap…